ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

Ann Thorac Surg 2000;70:936
© 2000 The Society of Thoracic Surgeons

Discussion

Discussion

Discussion

DR CAROLYN E. REED (Charleston, SC): Doctor Jones has presented a series of elegant studies that focus on a tremendously important subject, which is chemoresistance of non–small cell lung cancer. He is to be commended for this work. I would like to thank Dr Jones for sending me the manuscript in advance.

I have several questions for you, Dr Jones. If I am correct, nuclear factor-kappa B (NF-{kappa}B) upregulates a number of apoptosis inhibitors. Can you give us some insight into whether these inhibitors share a common mechanism of upregulation by NF-{kappa}B?

Two, how are you going to progress to in vivo experiments?

Three, is there any evidence that different histologic types of non–small cell lung cancer have differing levels of NF-{kappa}B?

Finally, what substance would you plan to use in vivo to target NF-{kappa}B?

I enjoyed your paper and I wish to thank you again for sending me the manuscript in advance and I look forward to further reports from your laboratory.

DR JONES: There . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2000 by The Society of Thoracic Surgeons.